Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Urothelial Cancer

Presenters

Koichiro Ogihara

Citation

Annals of Oncology (2019) 30 (suppl_9): ix71-ix76. 10.1093/annonc/mdz425

Authors

K. Ogihara1, E. Kikuchi2, T. Okabe3, S. Hattori4, R. Yamashita5, S. Yoshimine6, S. Shirotake3, K. Matsumoto2, R. Mizuno2, S. Hara4, M. Oyama3, M. Niwakawa5, M. Oya2

Author affiliations

  • 1 Urology, Keio University School of Medicine, 160-0016 - Tokyo/JP
  • 2 Urology, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 3 Uro-oncology, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP
  • 4 Urology, Kawasaki Municipal Hospital, 210-0013 - Kanagawa/JP
  • 5 Urology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 6 Urology, Saitama City Hospital, 336-8522 - Saitama/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 217P

Background

No reliable biomarker is available for predicting worse clinical outcome in chemo-resistant urothelial carcinoma (UC) patients treated with pembrolizumab. We focused on the neutrophil-lymphocyte ratio (NLR), which is reported to be a simple index of systemic inflammation and a possible biomarker for predicting prognosis in various malignancies, including UC. Our aim was to evaluate whether a high NLR level could predict subsequent clinical outcomes in chemo-resistant UC patients treated with pembrolizumab.

Methods

We identified 74 cases treated with pembrolizumab for chemo-resistant UC between December 2017 and April 2019 at our 5 institutions. We investigated the association between NLR levels and their prognosis. We defined patients with NLR of > 3.37 as the high NLR group according to a calculation by receiver-operating curve analysis.

Results

The high NLR group consisted of 30 cases (40.5%). The 6-month progression-free survival (PFS) rate for the high NLR group was 10.0±5.5%, which was significantly lower than that for their counterpart (44.8±7.8%, p < 0.001). Multivariate Cox regression analysis revealed that elevated NLR (p < 0.001) and liver metastases (p = 0.003) were independent indicators for disease progression. Furthermore, the 6-month cancer-specific survival (CSS) rate for the high NLR group (64.5±9.1%) was significantly lower than that for their counterpart (88.8±5.3%, p = 0.004). Multivariate analysis revealed that an elevated NLR was the only independent indicator for cancer-specific death (p = 0.008). The change of NLR level before and after pembrolizumab was elevated in 46 cases. The 6-month PFS and CSS rate for the increased NLR group (17.8±6.0% and 71.9±7.3%) was significantly lower than that for their counterpart (47.0±10.6% and 90.9±6.1%, p = 0.012 and p = 0.009).

Conclusions

Elevated NLR could identify a population with a poor response to pembrolizumab treatment among chemo-resistant UC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Koichiro Ogihara.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.